Mingjuan Hou is the vice president of Qualcomm. In her role, she leads and manages Qualcomm’s brand strategy, corporate communications, product marketing, digital communications, and media/industry analyst relations in China, and providing communications consel to senior management.

Mingjuan has more than 20 years of rich experience in corporate communications, branding, marketing strategy, digital communications, crisis management and public affairs.Since joining Qualcomm in 2002, she led the team successfully executing multiple branding and marketing campaigns and spearheaded long-term strategic collaborations with renowned IPs such as China National Geography and the KPL. These initiatives have significantly broadened and deepened the presence of Qualcomm’s corporate brand — as well as its product brands, Snapdragon® and Qualcomm Dragonwing™ — across more diverse, consumer-relevant touchpoints, which greatly enhance their awareness and reputation in the Chinese market. She led to establish Qualcomm’s corporate communications strategy and social media platforms in China, and helped develop co-marketing strategy with leading Chinese smart device makers, auto companies, e-commerce platforms, IoT vendors and many more. In addition, She is also a long-standing advocate for advancing women in technology. Leveraging her own career journey and Qualcomm’s best practices, she actively champions the empowerment of women and supports their continued growth, impact, and leadership across the tech industry.

Mingjuan is a recipient of a number of industry and corporate leadership awards, including 2023 Forbes China Top 100 Businesswomen, the Most Influential Businesswomen 2021 by Futune China, the Most Notable Businesswomen 2020 by Cyzone, the Mulan Yue Xianghui Empowerment Award 2024 by Xinhuanet, the Best 5G Practionioner 2020 by Communications World.

Ms. Li Ye is leading the Merck China Corporate Affairs hub in support to all the three business sectors (healthcare, life science & electronics) of Merck in China since January 2018. The China hub is among the 3 regional corporate affairs hubs (Europe, the United States and China) of Merck KGaA global wide. She is the member of the leadership team of Merck global corporate affairs and sits in the Country Council of Merck in China.

Ms. Li Ye is a veteran in corporate affairs and government relations for international companies with her 20+ years’ working experience. She joined Merck healthcare in Aug. 2013 responsible for the government relations and market access. Prior to that, she had been taking the management roles on government affairs, market access and strategic development in top international companies including Hoechst, GlaxoSmithKline, Bayer and AstraZeneca, etc. She went to Singapore as the Regional Market Access Lead in Bayer South East Asia in 2008. Later she became Regional Payer Capabilities Director and Global Pricing and Market Access Director for Oncology at AstraZeneca’s Asia Pacific Office until she returned to China.

Li Ye graduated from University of International Business and Economics in Beijing, then she went to the Great Britain for further study. She obtained a master’s degree in Business Administration from the University of Westminster, London. She also holds a Diploma of Economic Evaluation and Assessment in Health from the University of York, UK. In 2016, Li Ye completed her Executive MBA study in Peking University National Development School in Beijing. She is now studying for a doctorate on financial management run by the National Development School of Peking University and Fordham University in the United States.

As an opinion leader in the industry, Li Ye also holds the positions including：

Vice Chair of the China Association of Enterprises with Foreign Investment (CAEFI)
Vice Chair of the China Pharmaceutical Industry Association (CPIA)
National Chair of R&D Working Group, European Chamber of Commerce in China (EUCCC)
Executive Council Member of the Center for China and Globalization (CCG)

Linda Wang is the DVP & GM of Established Pharmaceuticals for Abbott China. She joined Abbott in 2024. In her current role, Linda is responsible for business development of Abbott’s established pharmaceuticals business in China market.

Prior to joining Abbott, Linda worked for several leading MNCs including Pfizer, BMS, Astellas, etc. Linda brings more than 20 years of commercial leadership experience in roles of progressing responsibility within the pharma industry in China and Asia Pacific markets. Her career highlights have included successful large organization management and brand management including product launches and brand life cycle management in multiple therapeutic areas including Oncology, Cardiovascular, Metabolic, Immunology, Virology, Anti-Infectives, Rare Disease, Vaccine, etc.

Linda holds a Bachelor of Veterinary Medicine from National Taiwan University and an MBA from the University of North Carolina at Charlotte.

Penny Hao Zheng is a distinguished leader with 17 years of extensive experience at GE and GE Vernova(after spin-off in 2024), marked by international assignments and a robust background in finance and leadership. Currently serving as the CFO for GE Vernova Gas Power Asia Services, she oversees a $2 billion portfolio, leading a team of 10 across more than 20 countries in APAC, South Asia, and China. Penny's early career involved impactful roles in corporate audit and research, holding a Master of Research in Functional Genomics and a Bachelor of Science in Biology from the University of York, Penny Zheng exemplifies women's leadership through her strategic vision, financial acumen, and global experience.

James Zimmerman is the Chairman of the American Chamber of Commerce in China (AmCham China).

Based in Beijing, James is a author and lawyer who has lived and worked in China for three decades. He is a partner with the law firm of Loeb & Loeb LLP and advises foreign companies on corporate, transactional, regulatory, litigation and white-collar criminal defense matters. James previously served as Chairman of AmCham China for four prior terms in 2007-08 and 2015-16. He is the author of the acclaimed non-fiction book, The Peking Express: The Bandits Who Stole a Train, Stunned the West, and Broke the Republic of China.